Compare JVA & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JVA | NXL |
|---|---|---|
| Founded | 1971 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0M | 18.6M |
| IPO Year | 2005 | 2022 |
| Metric | JVA | NXL |
|---|---|---|
| Price | $3.67 | $0.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 35.5K | ★ 117.7K |
| Earning Date | 01-30-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.91 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $89,748,681.00 | $156,931.00 |
| Revenue This Year | N/A | $38.28 |
| Revenue Next Year | N/A | $185.71 |
| P/E Ratio | $11.21 | ★ N/A |
| Revenue Growth | ★ 17.92 | N/A |
| 52 Week Low | $2.75 | $0.70 |
| 52 Week High | $9.93 | $3.87 |
| Indicator | JVA | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 49.02 | 32.96 |
| Support Level | $3.31 | $0.79 |
| Resistance Level | $3.74 | $1.01 |
| Average True Range (ATR) | 0.17 | 0.05 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 80.77 | 13.29 |
Coffee Holding Co Inc is engaged in wholesale coffee operations, including manufacturing, roasting, packaging, marketing, and distributing roasted and blended coffees for privately labeled accounts and its brands, and it sells green coffee. The Company also manufactures and sells coffee roasters. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada, and certain Asian countries. The group's services are Custom Blending, Food Service Programs, and Private Label Services.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.